Literature review · Muscle & strength

IGF-1 LR3

In a rat food-restriction experiment, higher retained body weight did not mean preserved skeletal-muscle protein. This distinction matters when evaluating growth-related claims.

By HeartPep · Reviewed · 2 selected source records

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

At a glance

The selected primary experiment is preclinical and short term. It provides a direct counterexample to treating a favourable weight marker as evidence of muscle preservation.

Identity & scope

LR 3 IGF-I is an IGF-I analogue. Findings on native IGF-I or another analogue should not be silently assigned to this material.

Catalogue labels covered: IGF-1 LR3.

What the research shows

  • The authors separately measured body weight, nitrogen balance and muscle-protein outcomes. Those measures did not all move in the same direction.

Critical interpretation

Body weight and muscle are not interchangeable outcomes

The food-restriction experiment measured several aspects of nutrient handling. Higher retained body weight and nitrogen did not prevent skeletal-muscle protein loss. This is why an anabolic headline needs the actual tissue and endpoint attached to it. The result applies to short-term restriction in rats; it neither proves a human benefit nor establishes that the compound can never have an anabolic effect in another model. [1]

Delivery and experimental stress change the comparison

The earlier study compared continuous delivery with injections in normally growing and dexamethasone-treated rats. LR3IGF-I’s relative potency varied by outcome, and stronger effects on some markers did not produce proportionately better reversal of carcass-muscle loss. Together, these studies show why binding-protein affinity or a body-weight response cannot serve as a shortcut to a human hypertrophy estimate. Species, nutritional state, induced catabolism and the method of exposure all remain part of the result. [2]

Limitations & uncertainties

  • The experiment cannot establish human muscle growth, strength or a treatment benefit.
  • Age and nutritional restriction affected the model’s response. It does not validate a supplied vial or nasal format.

Open research questions

  • Does a study measure muscle protein and function, or only body weight?
  • Is its molecule actually LR 3 IGF-I, and are its nutritional conditions relevant to the proposed experiment?

Selected papers & source records

Download bibliography
Animal studyNamed compoundAbstract / record checked

1. Insulin-like growth factor-I (IGF-I) analogue, LR(3)IGF-I, ameliorates the loss of body weight but not of skeletal muscle during food restriction (opens in a new tab)

Tomas FM. (2001). Growth Hormone & IGF Research. DOI: 10.1054/ghir.2000.0194 (opens in a new tab) · PMID 11472075

Design & population
Seven-day food-restriction experiment in young and adult rats receiving LR 3 IGF-I or vehicle.
What the study found
Treated animals retained more body weight and nitrogen, but skeletal-muscle protein loss was not prevented. Adult rats showed adverse changes in muscle-protein turnover under restriction.
Limits on interpretation
Animal experiment under restricted nutrition. Body weight and nitrogen retention were not evidence of preserved muscle, and findings cannot establish a human strength benefit.
Animal studyNamed compoundAbstract / record checked

2. Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection (opens in a new tab)

Tomas FM, Lemmey AB, Read LC, Ballard FJ. (1996). Journal of Endocrinology. DOI: 10.1677/joe.0.1500077 (opens in a new tab) · PMID 8708565

Design & population
Seven-day rat experiments comparing IGF-I with LR 3 IGF-I, continuous infusion with injection, and normal growth with dexamethasone-induced catabolism.
What the study found
Relative effects depended on delivery and endpoint. Greater effects on body weight or other markers did not mean proportionately greater reversal of carcass-muscle loss.
Limits on interpretation
Preclinical growth and catabolism models. Neither relative potency in rats nor delivery comparisons establish human muscle growth, strength or a validated nasal formulation.

Search & review scope

Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.. Checked 9 November 2026.

Selected primary research relevant to the named compound, its molecular specification and the endpoints described below.

Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research.

Recorded search terms
  • site.pubmed.ncbi.nlm.nih.gov/11472075/ (direct record check)
  • site.pubmed.ncbi.nlm.nih.gov "LR(3)IGF-I" "muscle" "rats"
  • "8708565" DOI authors

Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.

Cite this review

HeartPep. IGF-1 LR3: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/uk/research/library/igf-1-lr3.

HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

← All reviews and reference notes